Member Info for crowfoot

That’s why I wondering about a placement.

Rendj,
Most of the messages we are discussing including many of my own have been disappearing throughout the day. Make of that what you will.

Also I don't care if he's 19 or 39 pretending to be 19. Whatever floats your boat. I'm just here to discuss AEG and I don't mind a contrarian view just not your style of BS.

RoyalW,
Have you ever heard of Plato, Aristotle, Socrates? All 19 years old once upon a time so no need to be ageist.
You're just embarrassing yourself now. Are your family proud of you or do you tell them you do something important?

I've been reading their type of drivel for the last 2 decades so it's water off a duck's back for me. Very sad.

Thanks Bagga, no I hadn't seen it. Ignore the right RoyalW anker.

Agreed. So if PacifiCorp are satisfied with the performance and reorder a larger amount then there's no reason that it can't be 100% fulfilled from the Lumberton site with all revenue attributed solely to AEG.

Is it not 50% of a trial order as opposed to 50% of a major contract?
You can easily build up a decent short position with SpreadEx for example.

It's actually quite incredible how unloved and undervalued this share is. Last placement was August 2020 so perhaps something in the pipeline? Market cap of £9m seems crazy with all they have.

That's interesting. In reply to PF at 09:40 I created a thread titled 'Why do you start a new thread with a negative title every time you post...'
I also suggested not to reply to him on his threads because he is either short from February at around 1p or works for a company that has a short position. My thread was there for 10 mins and then removed. Hmmmm.

UPDATE: All posts regarding PotentForce other than his own threads are now removed!!!

All the information you need is in the RNS:

'The JV aims to operate beyond the time limits of the current temporary permit approved by the State of Maine and expects to successfully build and operate the Ashland Facility in order to produce up to 35,000 tonnes of CoalSwitchTM per year.'

'Building two CoalSwitchTM plants simultaneously has proven challenging for all parties but with the opportunity of completing two 5 tonne per hour CoalSwitchTM plants in different geographic locations in North America, future commercial milestones will be more easily achievable for AEG.'

Then just some basic maths will give you an answer of around 20 hours per day.

Slick Rick Da Rule - haha love it , that was a left field track off Charango.
'Look fat chicks I don't mean to sound rude, I tell her nice hit the gym and don't eat so much food'
Not one for the feminists (monkey covering eyes emoji :o)

Sorry, thought that had just been released!

FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
novel cancer therapies based on the Company’s proprietary Versamune(®)
T-cell activating technology, today announced publication of abstract #2501 by
the American Society of Clinical Oncology (ASCO). The abstract summarizing
interim data from the National Cancer Institute (NCI)-led phase 2 trial has
been accepted for oral presentation at the 2021 ASCO Annual Meeting taking
place June 4-8. The presentation, scheduled for June 7, is expected to include
results from a larger sample than the 14 patients included in the abstract.

Additional data highlights from abstract #2501 include:
* An overall objective response rate of 71% (10/14) in patients with
refractory HPV16-associated cancers * 1 complete response (anal cancer)
* 9 partial responses (3 cervical cancer, 2 vulvar/vaginal cancer, 2 anal
cancer, 2 oropharyngeal cancer)

* 90% of these of these responses are ongoing after a median 5 months of
follow up (9/10)
The NCI Center for Cancer Research’s Laboratory of Tumor Immunology and
Biology (LTIB) and Genitourinary Malignancies Branch (GMB) are jointly leading
this Phase 2 trial (NCT04287868), which studies PDS0101 in combination with
two investigational immune-modulating agents: bintrafusp alfa (M7824), a
bifunctional “trap” fusion protein targeting TGF-ß and PD-L1, and
NHS-IL12 (M9241), a tumor-targeting immunocytokine. Bintrafusp alfa is being
jointly developed by Merck KGaA, Darmstadt, Germany, and GlaxoSmithKline;
NHS-IL12 is being developed by Merck KGaA, Darmstadt, Germany.

The trial is evaluating the treatment combination in both checkpoint inhibitor
naïve and refractory patients with advanced human papillomavirus
(HPV)-associated cancers that have progressed or returned after treatment.
Objective response is measured by radiographic tumor responses according to
RECIST 1.1. These reported data validate the preclinical studies published by
the NCI demonstrating that the complementary mechanisms of action of the three
immunotherapies which involve potent in-vivo HPV16-specific killer and helper
T-cell induction with effective T-cell tumor infiltration, blocking of immune
checkpoints as well as targeting of TGF-ß resulted in superior tumor
regression.

“The achievement of a 71% objective response rate in a difficult to treat
patient population continues to strengthen the evidence of our novel
Versamune(®) platform’s potential ability to induce high levels of
tumor-specific CD8+ killer T-cells that attack the cancer resulting in strong
synergy with Bintrafusp alfa and NHS-IL12, thus leading to effective tumor
regression,” commented Dr. Lauren Wood, Chief Medical Officer of PDS
Biotech. “The initial data solidifies our belief that PDS0101’s published
preclinical efficacy, when combined with these two immune-modulating agents,
demonstrates the poten

Your glass in certainly half empty. If you are still a shareholder then you are clearly quite mad.
So within a few weeks we will have 2 operational plants and a direction for future growth. If Player can help achieve this quicker then it's no bad thing. Market cap £28m so still priced to fail in my opinion.

Back on now. Panic over! :o)

No quotes through Barclays either.

No online dealing through IG which is certainly not normal for a share dealing account but has happened before briefly.

Spot on SteJ, except I'm quite sure if you buy right now you will get the dividend.

The only question that actually matters for me is are we going to get a producing plant within the next couple of months? If you think the answer is no then perhaps you should sell. If yes then I think this is worth north of £28m. Changes can be made to the BOD at a later date if necessary. Obviously if you have a large financial position here it won't be pleasant in the very short term if bad news arrives regarding slippage.